Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Future Proof Brands, maker of the popular ready-to-drink brand BeatBox, is laying off over 150 employees at its headquarters. The move comes weeks after announcing a $490 million majority stake acquisition by Anheuser-Busch, signaling corporate restructuring ahead of the deal's expected close in early 2026.
A sharp sell-off grips both digital and traditional safe havens, with Bitcoin nearing a critical $80,000 level and gold suffering its worst drop in months, fueled by Fed uncertainty and tech sector anxieties.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
First Bank Corp. has entered into a definitive agreement to merge with Russellville-based First State Bank, a strategic move set to deepen the holding company's roots in the Arkansas River Valley region while preserving the community bank's local identity.
Months after the 'Crypto Black Friday' crash, allegations of platform instability and market manipulation continue to dog Binance, sparking fierce debate about trust and power in the digital asset space.
Wix.com Ltd. has launched a major share repurchase program as its stock trades near multi-year lows. While analysts have trimmed price targets, many maintain bullish ratings, citing significant upside potential and a more resilient outlook for SaaS companies in the face of AI disruption.
HubSpot (NYSE: HUBS) is drawing sustained bullish sentiment from Wall Street, with analysts highlighting its deepening penetration into the large enterprise segment as a key growth driver. Recent price target adjustments and partner commentary underscore confidence in the CRM platform's trajectory.
As the cryptocurrency market grapples with sustained selling pressure, a new analysis highlights significant vulnerabilities for two of the most recognizable digital assets, XRP and Dogecoin, projecting potential losses exceeding 50% in the coming year.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
Lean hog futures slipped lower on Friday, contrasting with a steady rise in the CME Lean Hog Index, as traders weighed softer cash prices against stronger wholesale pork values.
While Wall Street analysts are overwhelmingly bullish on several stocks, their optimistic price targets often come with a caveat. We examine one company where the enthusiasm appears justified and two where underlying challenges suggest a more cautious approach.
While consumer staples are traditionally seen as safe havens, recent underperformance against the broader market has spotlighted companies with weakening fundamentals. We examine three household names where valuation and growth concerns suggest caution is warranted.
In a market fixated on tech giants, savvy investors are looking to regional financial institutions for sustainable growth. We analyze two banks with strong momentum and one where caution may be warranted, against a backdrop of shifting interest rates and economic uncertainty.
While premium valuations often signal strong growth, they also set the stage for sharp corrections when investor sentiment cools. We examine three stocks where sky-high expectations may be outpacing fundamentals.
High valuations demand exceptional growth. We examine two companies whose business models justify the premium and one where the price may be running ahead of reality.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
While the small-cap index is a hunting ground for growth, some constituents face significant headwinds. We examine three companies where valuation and market dynamics warrant a cautious approach.
Profitability alone doesn't guarantee a winning stock. We examine three firms—Chewy, RH, and Proto Labs—that are in the black but face significant headwinds that may limit their future returns, prompting investors to look elsewhere for growth.